Prioritizing otological surgery during the COVID-19 Pandemic

The initial cases of pulmonary infection with the novel corona virus SARS-CoV-2, causing COVID-19, occurred in Wuhan, Hubei Province, China in December 2019 and January 2020 (1). The spread through human-to-human transmission has led to a pandemic with disastrous consequences all over the world. The exponential rate of transmission and no existing vaccine has been a great challenge for all health care systems. A strategy to flatten the curve of transmission was put forward to adjust to the capacities of hospitals and particularly the intensive care units. Governments implemented isolation and social distancing upon societies either with laws or with strong recommendations

Acupuncture for sequelae of Bell's palsy: a randomized controlled trial protocol

<p>Abstract</p> <p>Objective</p> <p>Incomplete recovery from facial palsy has a long-term impact on the quality of life, and medical options for the sequelae of Bell's palsy are limited. Invasive treatments and physiotherapy have been employed to relieve symptoms, but there is limited clinical evidence for their effectiveness. Acupuncture is widely used on Bell's palsy patients in East Asia, but there is insufficient evidence for its effectiveness on Bell's palsy sequelae. The objective is to evaluate the efficacy and safety of acupuncture in patients with sequelae of Bell's palsy.</p> <p>Method/Design</p> <p>This study consists of a randomized controlled trial with two parallel arms: an acupuncture group and a waitlist group. The acupuncture group will receive acupuncture treatment three times per week for a total of 24 sessions over 8 weeks. Participants in the waitlist group will not receive any acupuncture treatments during this 8 week period, but they will participate in the evaluations of symptoms at the start of the study, at 5 weeks and at 8 weeks after randomization, at which point the same treatment as the acupuncture group will be provided. The primary outcome will be analyzed by the change in the Facial Disability Index (FDI) from baseline to week eight. The secondary outcome measures will include FDI from baseline to week five, House-Brackmann Grade, lip mobility, and stiffness scales.</p> <p>Trial registration</p> <p>Current Controlled-Trials <a href="http://www.controlled-trials.com/ISRCTN43104115">ISRCTN43104115</a>; registration date: 06 July 2010; the date of the first patient's randomization: 04 August 2010</p